Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Rating)’s share price was down 5.4% during trading on Friday . The company traded as low as $0.92 and last traded at $0.93. Approximately 373,851 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 494,196 shares. The stock had previously closed at $0.98.
Seelos Therapeutics Trading Down 5.4 %
The stock has a fifty day moving average of $0.88 and a 200 day moving average of $0.96. The company has a market capitalization of $99.15 million, a P/E ratio of -1.17 and a beta of 2.04. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.85 and a current ratio of 1.85.
Seelos Therapeutics (NASDAQ:SEEL – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.18) EPS for the quarter. As a group, equities research analysts anticipate that Seelos Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.
Institutional Investors Weigh In On Seelos Therapeutics
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm’s portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.
- Get a free copy of the StockNews.com research report on Seelos Therapeutics (SEEL)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.